T Cell Non-Hodgkin Lymphoma — Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Citation(s)
Safety and Efficacy of Anti-CD7 CAR-Engineered T Cells for Relapsed/Refractory T Lymphoid Malignancies: a Single-center, Open-label, Non-randomized, Single-arm Clinical Study